BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zyga Technology, Inc. Announces Start of European Enrollment for the GLYDER(TM) Facet Resurfacing System Clinical Study


8/24/2011 10:48:08 AM

MINNEAPOLIS, Aug. 24, 2011 /PRNewswire/ -- Zyga Technology, Inc. announced today that the first European patients were enrolled and treated in its GLYDER Facet Resurfacing System Clinical Study.

(Logo: http://photos.prnewswire.com/prnh/20110118/CG30384LOGO)

The purpose of the GLYDER clinical study is to evaluate the safety and effectiveness of the GLYDER device in patients with a history of facet pain demonstrated by treatment history and diagnosis as a baseline. This is a prospective, multi-center clinical evaluation.

Professor Hans Jorg Meisel, M.D. Ph.D., Director, Center of Neurosciences/Chair, Department of Neurosurgery, BG-Clinic Bergmannstrost, Halle, Germany is the principal investigator for the study. "The GLYDER device was very easy to implant into the facet joints. Preoperatively, both of these patients had long lasting facet joint syndrome. The first postoperative examinations showed a good result concerning the patients' lumbar pain giving us the impression of a favorable outcome from the GLYDER surgery. We look forward to continuing the study and reporting the final results," said Professor Meisel.

Luiz Pimenta, M.D., Ph.D., Medical Director, Instituto de Patologia da Coluna, Sao Paulo, Brazil, who implanted the first-in-man GLYDER devices said, "Early results suggest that GLYDER could be a good option for treating patients suffering from facet pain. More study of this device is needed so we are looking forward to seeing the results from the European study."

Facetogenic pain has been shown to be the source of pain for up to 30% of patients suffering from low back pain. Patients who suffer from this condition typically receive therapeutic facet injections which temporarily address the problem but require long-term repeat treatments.

About Zyga Technology, Inc.

Zyga Technology, Inc. based in Minneapolis, MN, was founded to develop and market innovative, minimally invasive surgical solutions to treat conditions of the spine. Each year millions of people in the U.S. suffer from symptoms of back pain. Patients and physicians alike are demanding the latest innovations to treat back pain. Zyga Technology is responding to those challenges by delivering products and procedures that use the latest minimally invasive surgical techniques.

SOURCE Zyga Technology, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES